GLP-1 Drugs List 2026: Every FDA-Approved Brand and Price

What GLP-1 drugs are there, and which one is which? Here is the full list for the United States as of November 3, 2026. There are four main ingredients: semaglutide, tirzepatide, liraglutide and dulaglutide, plus the new pill orforglipron. They are sold under about a dozen brand names. Some are approved for weight loss and some only for type 2 diabetes. Three come as a pill. None is sold over the counter.

The tables below sort them by what they are approved for, then show how much weight people lost in the main trials and what they cost without insurance.

Names of GLP-1 drugs approved for weight loss

These are approved for chronic weight management in people with obesity, or with overweight plus a weight-related health problem, along with diet and exercise.

Zepbound is a little different. It acts on two gut hormones, GIP and GLP-1, so it is often called a dual agonist. It is still counted on GLP-1 lists. Our guide on GLP-1 vs GIP explains the difference.

GLP-1 drugs list for type 2 diabetes

These are approved to lower blood sugar in type 2 diabetes. Doctors sometimes prescribe them off-label for weight, but insurance often will not cover that.

For a side-by-side of the main shots, see our GLP-1 medication comparison. If you are comparing the two big diabetes shots, see Trulicity vs Ozempic. Mounjaro and Zepbound are the same medicine with two labels, which we cover in Zepbound vs Mounjaro.

GLP-1 drugs that were discontinued

Some older names still show up in search results but are no longer sold in the US.

These were business decisions, not safety recalls, according to payer notices. If you used one, your prescriber can move you to another option.

GLP-1 drugs list: pills vs shots

Most GLP-1 drugs are shots, but there are now three pills. Here is how they differ.

There is no Mounjaro or Zepbound pill. For details, see our Foundayo guide.

How much weight do people lose on each one?

These numbers come from each drug's main trial. The trials used different people and lengths, so they are not a fair race except where noted.

The only head-to-head weight-loss trial is SURMOUNT-5, where Zepbound led to 20.2% weight loss and Wegovy 2.4 mg to 13.7% at 72 weeks.

Here is the part the tables leave out. When you lose weight fast, some of it can be muscle. The trials that scanned body composition found that a real share of lost weight was lean mass. That is why protein and strength work matter on every drug on this list. Sharpy gives you one daily protein target and one 20-minute strength workout, and its Shape Score shows whether you are losing fat or muscle. Our protein target guide explains the math.

GLP-1 drugs list price

List prices are high, and insurance is the main way most people pay. These are the self-pay prices we checked in late October 2026. They change often, so confirm before you order.

For more detail, see our Wegovy pill cost guide. There is still no generic semaglutide in the US; our generic semaglutide guide explains why.

Is there a GLP-1 over the counter?

No. Every drug in this list needs a prescription. Products labeled "GLP-1 support" or "natural Ozempic" are supplements, not GLP-1 medicines. Compounded semaglutide and tirzepatide are not FDA approved, and the FDA does not check them for safety or quality before they are sold.

What is not on the list yet

• CagriSema (cagrilintide plus semaglutide, Novo Nordisk). Filed with the FDA in December 2025. A decision is expected in late 2026, but it is not approved as of November 3.
• Retatrutide (Eli Lilly). Still in trials. Lilly plans to file in early 2027. See our retatrutide guide.

Anything sold online under these names today is not an approved medicine.

Doctors can also prescribe any drug on this list for a use its label does not cover. Our guide to GLP-1 off label use explains what that means and what the evidence shows.

Safety basics that apply to the whole class

The shared warnings come from the labels. Semaglutide, tirzepatide, liraglutide, dulaglutide and orforglipron carry a boxed warning about thyroid C-cell tumors seen in rodents, and should not be used by people with a personal or family history of medullary thyroid cancer or MEN 2. The most common side effects across the class are nausea, diarrhea, vomiting and constipation, mostly while the dose goes up. If you are pregnant, planning a pregnancy, under 18 or have had an eating disorder, talk to your doctor first. Which drug and dose is right for you is your prescriber's decision.

The bottom line

The GLP-1 drugs list in the US now has seven options for weight loss, seven for type 2 diabetes, three pills and no over-the-counter choices. The drug matters, but so does what you eat and how you train while you take it. Sharpy keeps that part simple: one protein target, one 20-minute workout and one Shape Score a day.

Sources

• Novo Nordisk: Wegovy pill approved in the US (December 22, 2025, SEC filing)
• Becker's Hospital Review: FDA approves higher-dose Wegovy (March 2026)
• FDA approves Lilly's Foundayo (orforglipron), Eli Lilly via BioSpace, April 2026
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), NEJM 2022
• Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1), NEJM 2021
• Wharton S et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4), NEJM 2025
• Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE), NEJM 2015
• NBC News: Zepbound beats Wegovy in first head-to-head trial (SURMOUNT-5)
• UnitedHealthcare: Discontinuation of Bydureon BCise and Byetta (2024)
• OptumRx: Adlyxin market withdrawal notice (2023)
• Patient Care: First generic liraglutide approved for weight management (August 2025)